A major cause of morbidity and mortality, Chronic Obstructive Respiratory Disease (COPD) has now been identified as a multi-component disease with airway structural changes, mucociliary dysfunction, and airway inflammation with systemic effects in addition to airflow limitation, which suggests the need for a multi-targeted treatment approach.
Triohale rotacaps contain 18 mcg of tiotropium, 12 mcg of formoterol and 400 mcg of ciclesonide. With the combination of an anticholinergic, long acting beta2 agonist and corticosteroid, Triohale rotacaps target the multiple components of COPD. Triohale is already available as a pressurized metered dose inhaler (pMDI).
Evidence from clinical studies suggests that triple drug therapy is associated with improvements in lung function and the quality of life, reduction in the number of exacerbations and use of reliever medications.
The availability of a triple drug combination of tiotropium, formoterol with ciclesonide would be an advance over the currently available range of products for COPD, especially for patients with severe COPD who currently have to use multiple devices. This would be coupled with the added benefit of increased compliance with treatment as a combination would ensure all the three drugs would be taken and a possible reduction in cost of therapy.
The recommended dosage of Triohale rotacaps is one rotacap inhaled once daily, using the Cipla Rotahaler/ Revolizer.
Reviews
There are no reviews yet.